Royal Bank Of Canada Aravive, Inc. Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.11 - $0.22 $8 - $16	-75 Reduced 14.56%	440 $0
Q3 2023 Nov 14, 2023	SELL	$0.11 - $1.76 $90 - $1,446	-822 Reduced 61.48%	515 $0
Q2 2023 Aug 14, 2023	BUY	$1.25 - $1.92 $1,671 - $2,567	1,337 New	1,337 $1,000
Q3 2022 Nov 14, 2022	BUY	$0.61 - $1.03 $154 - $261	254 New	254 $0
Q4 2021 Feb 14, 2022	SELL	$2.19 - $4.07 $72 - $134	-33 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$3.67 - $5.8 $8,224 - $12,997	-2,241 Reduced 98.55%	33 $0
Q2 2021 Aug 16, 2021	BUY	$4.65 - $6.42 $10,574 - $14,599	2,274 New	2,274 $14,000

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.